Dr. Nikolaos Almyroudis, MD

Dr. Almyroudis practices at Roswell Park Cancer Institute in Los Angeles, California.

Dr. Almyroudis' NPI, 1962407163, was assigned on June 15, 2005. Dr. Almyroudis holds New York license 270806.

Dr. Almyroudis' primary practice is Roswell Park Cancer Institute, at 344 S Hauser Blvd, Los Angeles, CA 90036 in Los Angeles County. The practice phone is (716) 845-2300.

Dr. Almyroudis' primary practice is Roswell Park Cancer Institute in Los Angeles, California. Dr. Almyroudis is also affiliated with Roswell Park Comprehensive Cancer Center. The medical group on file is Roswell Park Comprehensive Cancer Center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Almyroudis practices. Vendor and product names are available with a free account.

Infectious disease is Dr. Almyroudis' primary specialty in the NPI Registry, under taxonomy code 207RI0200X. Dr. Almyroudis is licensed in New York.

CMS data shows 129 Medicare services from Dr. Almyroudis across 5 procedure codes in 2024, for 76 Medicare patients. Medicare paid $11,907 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 76 Medicare patients who saw Dr. Almyroudis in 2024. The largest group is 65 to 74, with 38 patients. 75% of them have high blood pressure, and 74% have high cholesterol. 16% are also on Medicaid. Their average risk score is 3.52, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Almyroudis' median patient age at 71, with 37% women.

In 2024, Dr. Almyroudis wrote 228 Medicare Part D claims for 40 patients. 81% of them were for generic drugs. CMS names the drug for 154 of them, across 8 drugs with 11 or more claims each, at $97,955 in total drug cost. In 2023, CMS named 104 claims across 7 drugs.

Dr. Almyroudis accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 16 papers to Dr. Almyroudis, published from 2006 to 2025. 2011 was the busiest year, with 2. The most frequent topics are Anti-Bacterial Agents. Dr. Almyroudis' most frequent co-authors are Philip Louis McCarthy, MD, John P. Bonnewell, MD and Maureen Ross, MD, PhD.

CMS Open Payments shows 10 general payments to Dr. Almyroudis from 2 drug and device companies from 2021 to 2025. Education make up the largest share, 100% of the total. Insmed, Inc. paid the most, $146.